Effects of Celastrol on the Heart and Liver Galaninergic System Expression in a Mouse Model of Western-type Diet-induced Obesity and Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis

Overview

Journal Front Pharmacol

Date 2025 Feb 19

PMID 39968178

Authors

Nikolina Canova

Jana Sipkova

Mahak Arora

Zuzana Pavlikova

Tomas Kucera

Ondrej Seda

Tijana Sopin

Tomas Vacik

Ondrej Slanar

Affiliations

Soon will be listed here.

Abstract

Background: The complexity of the galaninergic system is still not fully understood, especially under specific pre-existing comorbidities related to metabolic dysfunction. A plant-derived triterpenoid celastrol was demonstrated to exert a complex effect on the galaninergic system and to have hepatoprotective and anti-obesity properties. However, the exact molecular mechanisms responsible for these effects remain unclear. Specifically, there are no data on the impact of celastrol on the heart and liver galaninergic system. Therefore, this study aimed to investigate the effects of celastrol on the galaninergic system expression in the heart and liver of mice suffering from diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH).

Methods: The male mice C57BL/6J were fed a Western-type high-fat diet for 16 and 20 weeks to induce obesity and MASLD/MASH. Celastrol was administered along with a specific diet for the last 4 weeks to evaluate its impact on the progression of these conditions. Moreover, the inhibitor of sterol regulatory element-binding protein 1/2 (SREBP1/2), fatostatin, was also tested to compare its influence on the galaninergic system with celastrol.

Results: The study demonstrates that celastrol treatment was safe and led to a reduction in food and energy intake, body fat and liver weights, and MASLD-to-MASH progression and improved glucose tolerance, serum biochemistry markers, and hepatic lipid peroxidation in mice. Quantitative gene expression originally showed significant regulation of galanin and all three of its receptors (GalR1/2/3) in the heart ventricles and only GalR2 in the liver of obese mice. Celastrol influenced the gene expression of galanin receptors: it downregulated in the heart and upregulated in the liver and in the heart ventricles, potentially affecting energy metabolism, oxidative stress, and inflammation. Fatostatin suppressed gene expression of all the detected members of the galaninergic system in the heart ventricles, depicting the role of SREBP in this process.

Conclusion: These findings suggest that celastrol may beneficially modulate the galaninergic system under obesity and MASLD-to-MASH progression, indicating its potential as a therapeutic agent for disorders associated with metabolic dysfunction.

References

Jacobsen D, Montoya M, Llewellyn T, Martinez K, Wilding K, Lenz K . Correlating transcription and protein expression profiles of immune biomarkers following lipopolysaccharide exposure in lung epithelial cells. PLoS One. 2024; 19(4):e0293680. PMC: 11037529. DOI: 10.1371/journal.pone.0293680. View

Andrikopoulos S, Blair A, Deluca N, Fam B, Proietto J . Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 2008; 295(6):E1323-32. DOI: 10.1152/ajpendo.90617.2008. View

Lee J, Koo T, Yoon H, Jung H, Jin H, Lee K . Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol. 2006; 72(10):1311-21. DOI: 10.1016/j.bcp.2006.08.014. View

Molla M, Dessie G, Akalu Y, Ayelign B . Hepatocellular Expression of SIRT1 and Its Effect on Hepatocellular Carcinoma Progression: A Future Therapeutic Perspective. Int J Hepatol. 2020; 2020:2374615. PMC: 7315277. DOI: 10.1155/2020/2374615. View

Stankova P, Kucera O, Peterova E, Elkalaf M, Rychtrmoc D, Melek J . Western Diet Decreases the Liver Mitochondrial Oxidative Flux of Succinate: Insight from a Murine NAFLD Model. Int J Mol Sci. 2021; 22(13). PMC: 8268937. DOI: 10.3390/ijms22136908. View

Zorrilla E, Brennan M, Sabino V, Lu X, Bartfai T . Galanin type 1 receptor knockout mice show altered responses to high-fat diet and glucose challenge. Physiol Behav. 2007; 91(5):479-85. PMC: 2080849. DOI: 10.1016/j.physbeh.2006.11.011. View

Kim S, Sohn I, Ahn J, Lee K, Lee Y, Lee Y . Hepatic gene expression profiles in a long-term high-fat diet-induced obesity mouse model. Gene. 2004; 340(1):99-109. DOI: 10.1016/j.gene.2004.06.015. View

Gopalakrishnan L, Chatterjee O, Raj C, Pullimamidi D, Advani J, Mahadevan A . An assembly of galanin-galanin receptor signaling network. J Cell Commun Signal. 2020; 15(2):269-275. PMC: 7990979. DOI: 10.1007/s12079-020-00590-3. View

Abebe E, Mengstie M, Seid M, Malik T, Dejenie T . The evolving roles of alarin in physiological and disease conditions, and its future potential clinical implications. Front Endocrinol (Lausanne). 2022; 13:1028982. PMC: 9556965. DOI: 10.3389/fendo.2022.1028982. View

10.

Abu Bakar M, Nor Shahril N, Mohamad Khalid M, Mohammad S, Shariff K, Karunakaran T . Celastrol alleviates high-fat diet-induced obesity via enhanced muscle glucose utilization and mitochondrial oxidative metabolism-mediated upregulation of pyruvate dehydrogenase complex. Toxicol Appl Pharmacol. 2022; 449:116099. DOI: 10.1016/j.taap.2022.116099. View

11.

Lang R, Gundlach A, Holmes F, Hobson S, Wynick D, Hokfelt T . Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev. 2014; 67(1):118-75. DOI: 10.1124/pr.112.006536. View

12.

Fan N, Zhao J, Zhao W, Shen Y, Song Q, Shum H . Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice. Biomater Sci. 2022; 10(4):984-996. DOI: 10.1039/d1bm01637g. View

13.

Zhao Q, Lin X, Wang G . Targeting SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer. Front Oncol. 2022; 12:952371. PMC: 9330218. DOI: 10.3389/fonc.2022.952371. View

14.

Eng P, Forlano R, Tan T, Manousou P, Dhillo W, Izzi-Engbeaya C . Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts. JHEP Rep. 2023; 5(10):100835. PMC: 10522907. DOI: 10.1016/j.jhepr.2023.100835. View

15.

Palkeeva M, Studneva I, Molokoedov A, Serebryakova L, Veselova O, Ovchinnikov M . Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury. Biomed Pharmacother. 2018; 109:1556-1562. DOI: 10.1016/j.biopha.2018.09.182. View

16.

Hu J, Li X, Zhou J, Zhang C, Zheng G, Qiu Z . Celastrol delays hepatic steatosis and carcinogenesis in a rapid AKT/c-Met-transfected hepatocellular carcinoma model suppressing fatty acid synthase expression and AKT/ERK phosphorylation. RSC Adv. 2022; 8(25):13976-13983. PMC: 9079895. DOI: 10.1039/c8ra00522b. View

17.

Fang P, Yu M, Shi M, Bo P, Zhang Z . Galanin peptide family regulation of glucose metabolism. Front Neuroendocrinol. 2019; 56:100801. DOI: 10.1016/j.yfrne.2019.100801. View

18.

Sciolino N, Smith J, Stranahan A, Freeman K, Edwards G, Weinshenker D . Galanin mediates features of neural and behavioral stress resilience afforded by exercise. Neuropharmacology. 2014; 89:255-64. PMC: 4250306. DOI: 10.1016/j.neuropharm.2014.09.029. View

19.

Berger A, Lang R, Moritz K, Santic R, Hermann A, Sperl W . Galanin receptor subtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology. 2003; 145(2):500-7. DOI: 10.1210/en.2003-0649. View

20.

Tofighi R, Joseph B, Xia S, Xu Z, Hamberger B, Hokfelt T . Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci U S A. 2008; 105(7):2717-22. PMC: 2268202. DOI: 10.1073/pnas.0712300105. View